Pediatric Oncology Fellowship
*Applications will be reviewed on a rolling-basis.
A research opportunity is available in the Office of New Drug / Office of Hematology and Oncology Products, Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA) in Silver Spring, Maryland.
This project, located in the Office of New Drugs, will focus on investigating the glycans of Ewing's Sarcoma (EWS) cell lines and primary EWS tissue samples to identify and characterize unique glycan structures, assess the molecular changes involved with the altered glycosylations, and establish clinically useful glyco-biomarkers for EWS.
The participant will train with an experienced research group to investigate glycan biomarkers for Ewing’s Sarcoma (EWS), a pediatric malignancy. The laboratory’s research program crosses the boundaries of biochemistry, molecular biology, glycobiology, and biotherapeutics. In particular, the laboratory is developing platforms to assess aberrant glycosylations in cancer as potential therapeutic targets. The participant will gain a broad scientific understanding of mammalian glycobiology and neoplasia associated alterations of glycans in tumorigenesis. The participant will also gain new, or additional experience in HPLC Tandem MS and other molecular biological techniques used in analyzing glycan expression, structure, and function.
Qualifications
The qualified candidate should have received a doctoral degree in one of the relevant fields. Degree must have been received within five years of the appointment start date.
Prior experience with mass spectrometry is desired.
If you have questions, send an email to ORISE.FDA.CDER@orau.org. Please include the reference code for this opportunity (FDA-CDER-2020-0511) in your email.